Hypercoagulability and hyperfibrinolysis in patients with melanoma

B. Bottasso, D. Mari, R. Coppola, N. Santoro, M. Vaglini, Pier Mannuccio Mannucci

Research output: Contribution to journalArticlepeer-review


The purpose of this study was to evaluate whether or not, using sensitive analytical methods for the measurement of coagulation and fibrinolysis enzyme activity, there was a hypercoagulable state in patients with melanoma, and whether differences existed between those with or without metastases. Seventy-one patients were studied, 45 with localized tumors (stages Ia and Ib) and 26 with metastases (stages II-IV). Plasma level of activated factor VII, prothrombin fragment 1+2, thrombin-antithrombin complex, fibrinopeptide A, plasmin-antiplasmin complex and D-dimer were much higher in the whole group of 71 patients than in 45 controls with benign nevi. However, when melanoma patients with or without metastases were compared, there were smaller differences, with only thrombin-antithrombin complex, plasmin-antiplasmin and D-dimer significantly higher in metastatic melanoma. These results indicate that in patients carrying a tumor endowed with high procoagulant activity in vitro, there is a laboratory picture of hypercoagulability with secondary hyperfibrinolysis in vivo. However, differences between patients with localized and metastatic tumors for markers of hypercoagulability are not striking, in spite of the fact that metastatic cells support greater coagulant activity than primary cells in vitro.

Original languageEnglish
Pages (from-to)345-352
Number of pages8
JournalThrombosis Research
Issue number3
Publication statusPublished - Feb 1 1996


  • activated factor VII
  • hypercoagulability
  • melanoma

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology


Dive into the research topics of 'Hypercoagulability and hyperfibrinolysis in patients with melanoma'. Together they form a unique fingerprint.

Cite this